Article Data

  • Views 251
  • Dowloads 107

Original Research

Open Access

Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations

  • F. Amant12,*,
  • L. Dreyer3
  • J. Makin1
  • I. Vergote2
  • B. G. Lindeque1

1Department cif Obstetrics and Gynaecology, Pretoria Academic Hospital, Pretoria, South Africa

2Division of Gynaecological Oncology from the Department of Obstetrics and Gynaecology, University Hospitals Leuven, Belgium

3Department of Anatomical Pathology, University of Pretoria, Pretoria, South Africa

DOI: 10.12892/ejgo200103194 Vol.22,Issue 3,May 2001 pp.194-200

Published: 10 May 2001

*Corresponding Author(s): F. Amant E-mail:

Abstract

Background: There is considerable evidence for a higher incidence of uterine sarcomas in blacks when compared to whites. However, whether this higher incidence is related to differences in clinicopathologic presentation is not known.

Patients and methods: We reviewed slides and clinical charts of 81 patients with a primary diagnosis of uterine sarcoma referred between 1991 and 1999 to Kalafong Academic and Pretoria Academic Hospital. After review, 49 cases remained for study.

Results: Uterine sarcomas were distributed between leiomyosarcoma (LMS) (39%), carcinosarcoma (CS) (49%) and endometrial stromal sarcoma (ESS) (12%). LMS and ESS tend to present at an earlier age when compared to CS (respectively p < 0.008 and 0.02). Of women with LMS more women are premenopausal when compared to CS (p < 0.009). Lower abdominal pain is more common in LMS (p < 0.009), whereas bleeding is more common in women suffering from CS (p < 0.01). Lymphovascular space involvement and cervical involvement are more common in CS when compared to LMS. In CS, the carcinoma component has most of the metastatic potential.

Conclusion: Among black South African women different clinicopathologic features for uterine LMS, CS and ESS are observed. We also present genetic and/or hormonal factors possibly contributing to the pathophysiology of uterine sarcomas in blacks.

Keywords

Uterine sarcoma; Leiomyosarcoma; Carcinosarcoma; Endometrial stromal sarcoma; Race; Ethnic

Cite and Share

F. Amant,L. Dreyer,J. Makin,I. Vergote,B. G. Lindeque. Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations. European Journal of Gynaecological Oncology. 2001. 22(3);194-200.

References

[1] Powell l.J., Banerjee M., Sakr W. et al.: "Should African-American men be tested for prostate carcinoma at an earlier age than white men?" Cancer, 1999, 85, 472.

[2] Troisi R.J., Freedman A.N., Devesa S.S.: "Incidence of colorectal carcinoma in the US. An update of trends by gender, race, age, subsite and stage, 1975-1994". Cancer, 1999, 85, 1670.

[3] Newman L.A., Alfonso A.E.: "Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital". Ann. Surg. Oncol., 1997, 4(8), 655.

[4] Cramer D.W., Cutler S.J.: "Incidence and histopathology of malignancies of the female genital organs in the United States". Am. J. Obstet. Gynecol., 1974, 118, 443.

[5] Bain R.P., Greenberg R.S., Chung K.C.: "Racial differences in survival of women with endometrial cancer". Am. J. Obstet. Gynecol., 1987, 157, 914.

[6] Zaloudek C., Nonis H.J.: "Mesenchymal tumors of the uterus". In: Kurrnan R.J., ed. Blaustein's Pathology of the Female Genital Tract. New-York: Springer-Verlag, fourth edition, 1994, 487.

[7] Disaia P.J., Creasman W.T.: "Sarcoma of the uterus". In: Disaia P.J., Creasman W.T., eds. Clinical Gynecologic Oncology. St. Louis, Missouri: Mosby, fifth edition, 1997, 169.

[8] Christopherson W.M., Williamson E.0., Gray L.A.: "Leiomyosarcoma of the uterus". Cancer, 1972, 29, 1512.

[9] Harlow B.L., Weiss N.S., Lofton S.: "The epidemiology of sarcomas of the uterus". J. Natl. Cancer inst., 1986, 76(3), 399.

[10] Schwartz S.M., Weiss N.S., Daling J.R. et al.: "Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus". Cancer, 1996, 77(4), 717.

[11] Williamson E.0., Christopherson W.M.: "Malignant mixed miillerian tumours of the uterus". Cancer, 1972, 29, 585.

[12] Zelmanowics A., Hildesheim A., Sherman M.E. et al.: "Evidence for a common etiology for endometrial carcinomas and malignant mixed Miillerian tumors". Gynecol. Oncol., 1998, 69, 253.

[13] Bell S.W., Kempson R.L., Hendrickson M.R.: "Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases". Am. J. Surg. Pathol., 1994, 18(6), 535.

[14] Hrynchak M., Horsman D., Salski C., Berean K., Benedet J.L.: "Complex karyotypic alterations in an endometrial stromal sarcoma". Cancer Genet. Cytogenet.,1994, 77, 45.

[15] Laxman R., Currie J.L., Kurman R.J., Dudzinski M., Griffin C.A.: "Cytogenetic profile of uterine sarcomas". Cancer, 1993, 71(4), 1283.

[16] Nilbert M., Mandahl N., Heim S. et al.: "Complex karyotypic changes, including rearrangements of 12q l 3 and 14q24, in two leiomyosarcomas". Cancer Genet. Cytogenet., 1990, 48, 217.

[17] Dal Cin P., Boghosian L., Crickard K., Sandberg A.A.: "T(10;17) as the sole chromosome change in a uterine leiomyosarcoma". Cancer Genet. Cytogenet., 1988, 32, 263.

[18] Dal Cin P.,Talcott J., Abrams J., Li F.P., Sandberg A.A.: "Ins( l 0;19) in an endometrial stromal sarcoma". Cancer Genet. Cytogenet., 1988, 36, 1.

[19] Shields P.G., Caporaso N.E., Falk R.T. et al.: "Lung cancer, race, and a CYPIAI genetic polymorphism". Cancer Epidemiology, Biomarkers & Prevention, 1993, 2(5), 481.

[20] Bhatia K.G., Cherney B.W., Huppi K. et al.: "A deletion linked to a poly(ADP-ribose) polymerase gene on chromosome 13q33-qter occurs frequently in the normal black population as well as in multiple tumor DNA". Cancer Res., 1990, 50, 5406.

[21] Lyn D., Cherney B.W., Lalande M. et al.: "A duplicated region is responsible for the poly(ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predisposition to cancer". Am. J. Hum. Genet., 1993, 52(1), 124.

[22] Little C.D., Nau M.M., Carney D.N., Gazdar A.F., Minna J.D.: "Amplification and expression of the c-myc oncogene in human lung cancer cell lines". Nature, 1983, 306, 194.

[23] Riou G., Le M.G., Le Doussal V., Barrois M., George M., Haie C.: "C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix". Lancet, 1987, 8536, 761.

[24] De Vos S., Wilczynski S.P., Fleishhacker M., Koeffler P.: "p53 alterations in uterine leiomyosarcomas versus leiomyomas". Gynecol. Oncol., 1994, 54, 205.

[25] Jeffers M.D., Farquharson M.A., Richmond J.A., McNicol M.: "p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus". J. Pathol., 1995, 177, 65.

[26] Liu F.-S., Kohler M.F., Marks J.R., Bast R.C., Boyd J., Berchuck A.: "Mutation and overexpression of the P53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas". Obstet. Gynecol., 1994, 83, 118.

[27] Nordal R.R., Kristensen G.B., Stenwig A.E., Trope C.G., Nesland J.M.: "lmmunohistochemical analysis of p53 protein in uterine sarcomas". Gynecol. Oneal., 1998, 70, 45.

[28] Kohler M.F., Carney P., Dodge R. et al.: "P53 overexpression in advanced-stage endometrial adenocarcinoma". Am. J. Obstet. Gynecol., 1996, 175, 1246.

[29] Quade B.J., Pinto A.P., Howard D.R., Peters W.A., Crum C.P.: "Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma". Am. J. Path., 1999, 154, 945.

[30] Steck P.A., Pershouse M.A., Jasser S.A. et al.: "Identification of a candidate tumour suppressor gene, MMAC I, at chromosome 10q23.3 that is mutated in multiple advanced cancers". Nat. Genet., 1997, 15, 356.

[31] Bradlow H.L., Davis D.L., Lin G., Sepkovic D.W., Timari R.: "Effects of pesticides on the ratio of 16-hydroxyestrone: a biologic marker of breast cancer risk". Environ. Health. Perspect., 1995, 103, 147.

[32] Davis D.L., Bradlow H.L., Wolff M., Woodruff T., Hoel D.G., Anton-Culver H.: "Medical hypothesis: xenoestrogens as preventable causes of breast cancer". Environ. Health Perspect., 1993, 101, 372.

[33] Taioli E., Garte S.J., Trachman J. et al.: "Ethnic differences in estrogen metabolism in healthy women". J. Natl. Cancer Inst.,1996, 88(9), 617.

[34] Woods M.N., Barnett J.B., Spiegelman D. et al.: "Hormone levels during dietary changes in premenopausal African-American women". J. Nat. Cancer Inst., 1996, 88(19), 1369.

[35] Altaras M.M., Jaffe R., Cohen I., Gruber A., Yanai-lnbar I., Bernheim J.: "Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: two cases and a review of the literature". Gynecol. Oneal., 1990, 38, 273.

[36] Press M.F., Scully R.E.: "Endometrial'sarcomas' complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy". Gynecol. Oneal., 1985, 21, 135.

[37] Bekkers R.L., Massuger L.F., van der Berg P.P., van Haelst U.G., Bulten J.: "Uterine malignant leiomyoblastoma (epihelioid leiomyosarcoma) during pregnancy". Gynecol. Oneal., 1999, 72, 433.

[38] Briand P., Hou-Jensen K., Thorpe S.M., Rose C.: "Hormonedependent uterine sarcomas in GR mice". Eur. J. Cancer, 1981, 17(6), 635.

[39] Beer T.W., Buchanan R., Buckley C.H.: "Uterine stromal sarcoma following tarnoxifen treatment". J. Clin. Path., 1995, 48, 596.

[40] Eddy G.L., Mazur M.T.: "Endolymphatic stromal myosis associated with tamoxifen use". Gynecol. Oneal., 1997, 64(2), 262.

[41] Altaras M.M.,A virarn R.,C ohen I.,C ordoba M.,Y arkoni S.,Beyth Y.: "Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas". Gynecol. Oneal., 1993, 49, 255.

[42] Clarke M.R.: "Uterine malignant mixed Mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer". Gynecol. Oncol., 1993, 51, 411.

[43] Clement P.B., Oliva E., Young R.H.: "Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions". Int. J. Gynecol. Path., 1996, 15, 222.

[44] Sasco A.J., Raffi F., Satge D., Goburdhun J., Fallouh B., Leduc B.: "Endometrial mullerian carcinosarcoma after cessation of tarnoxifen therapy for breast cancer". Int. J. Gynecol. Obstet., 1995, 48, 307.

[45] Seoud M., Johnson J., Weed J.C.: "Gynecologic tumors in tamoxifen-treated women with breast cancer". Obstet. Gynecol., 1993, 82, 165.

[46] Gillett D.: "Leiomyosarcoma of the uterus in a woman taking adjuvant tamoxifen therapy". Med. J. Aust., 1995, 163, 160.

[47] Loong E.P.,W ong F.W.: "Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid". Fertil. Steril., 1990, 54(3), 530.

[48] Mesia A.F., Williams F.S., Yan Z., Mittal K.: "Aborted le10myosarcoma after treatment with leuprolide acetate". Obstet. Gynecol., 1998, 92, 664.

[49] Kjerulff K.H., Langenberg P.L., Seidman J.D., Stolley P.D., Guzinsky G.M.: "Uterine leiomyomas. Racial d计ferences in severity, symptoms and age at diagnosis." J. Reprod. Med., 1996, 41, 483.

[50] Marshall L.M., Spiegelman D., Barbieri R.L. et al.: "Variation in the incidence of uterine leiomyoma among premenopausal women by age and race". Ohstet. Gynecol., 1997, 90(6), 967.

[51] Major F.J., Blessing J.A., Silverberg S.G. et al.: "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer, 1993, 71, 1702.

[52] Barter J.F., Smith E.B., Szpak C.A., Hinshaw W., Clarke-Pearson D.L., Creasman W.T.: "Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases". Gynecol. Oneal., 1985, 21, 220.

[53] Kahanpaa K.V., Wahlstrom T., Grohn P., Heinonen E., Nieminen U., Widholm 0.: "Sarcomas of the uterus: a clinicopathologic study of 119 patients". Obstet. Gynecol., 1986, 67, 417.

[54] Larson B., Silfversward C., Nilsson B., Pettersson F.: "Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981" Acta. Oneal., 1990, 29, 185.

[55] Olah K.S., Blunt S., Dunn J.A., Kelly K., Chan K.K.: "Retrospective analysis of 318 cases of uterine sarcoma". Eur. J. Cancer, 1991, 27(9), 1095.

[56] Macasaet M.A., Waxman M., F ruchter R.G. et al.: "Prognostic factors in malignant mesodermal (Mullerian) mixed tumors of the uterus". Gynecol. Oneal., 1985, 20, 32.

[57] Bitterman P., Byungkyu C., Kurrnan R.J.: "The significance of epithelial differentiation in mixed rnesoderrnal tumors of the uterus". Am. J. Surg. Path., 1990, 14(4), 317.

[58] Silverberg S.G., Major F.J., Blessing J.A. et al.: "Carcrnosarcorna (Malignant Mixed Mesoderrnal Tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases". Int. J Gynecol. Pathol., 1990, 9, 1.

[59] Meis J.M., Lawrence W.D.: "The immunohistochernical profile of malignant mixed Mullerian tumor". Am. J. Clin. Pathol., 1990, 94, 1.

[60] Rose P.O., Piver M.S., Tsukada Y., Lau T.: "Patterns of metastasis in uterine sarcoma. An autopsy study". Cancer, 1989, 63, 935.

[61] Fleming W.P., Peters W.A., Kumar N.B., Morley G.W.: "Autopsy findings in patients with uterine sarcoma". Gynecol. Oneal., 1984, 19, 168.

[62] Meredith R.F.,E isert D.R.,K aka Z.,H odgson S.E.,J ohnston G.A., Boutselis J.G.: "An excess of uterine sarcomas after pelvic irradiation". Cancer, 1986, 58, 2003.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top